TGFB1 and Alzheimer disease: Such pathways included those annotated to describe histone modification with arginine deiminase activity, serine-type hydrolase activity, and TGF-β signaling (Table S5); all of which were previously associated with AD (30, 31) or have been suggested as potential pharmacologic targets (32).